Interferon Beta

BreastfeedingPediatric
  • TRADE NAMES: Avonex (Biogen); Betaferon (Bayer); Betaseron (Bayer); Extavia; Plegridy (Biogen); Rebif (Merck)
  • INDICATIONS: Relapsing multiple sclerosis, cancers
  • CLASS: Immunomodulator, Interferon
  • HALF-LIFE: 10 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Theophylline, Theophylline derivatives, Zidovudine

PREGNANCY CATEGORY: C

Our database has 110 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric